Clinical trials
Muscle-Invasive Bladder Carcinoma clinical trials
Below are recruiting muscle-invasive bladder carcinoma clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07339761Recruiting
Sexual health support for bladder cancer patients
This study from the University of Aarhus looks at ways to support sexual health in people who have been treated for bladder cancer. If you are a Danish-speaking adult who had bladder cancer treatment about a year ago and have noticed changes in sexual function, you may be able to join.
AarhusAges 18 years+ - NCT07475403RecruitingPhase 2
Immunotherapy guided by urine DNA for high risk bladder cancer
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
TianjinAges 18 years+ - NCT07646145RecruitingPhase 2
Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Taiyuan, ShanxiAges 18 years+ - NCT07647289RecruitingPhase 2
Immunotherapy plus chemotherapy before bladder cancer surgery
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT06525571RecruitingPhase 3
Blue light surgery for high-risk bladder cancer
This trial tests if using blue light during surgery helps remove all cancer in people with high-risk non-muscle invasive bladder cancer. It may lower the chance of the cancer coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Phoenix, ArizonaAges 18 years+ - NCT06972615RecruitingPhase 2
Bladder chemo plus pembrolizumab for BCG-treated cancer
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
CABAAges 18 years+ - NCT04574960RecruitingPhase 3
Neoadjuvant chemotherapy before kidney/ureter cancer surgery
This Phase 3 trial studies giving cisplatin-based chemotherapy before surgery for certain newly diagnosed upper-urinary-tract urothelial cancers (kidney/ureter). It may help shrink the cancer and improve outcomes by treating microscopic disease earlier.
Ottawa, OntarioAges 18 years+ - NCT06971614RecruitingPhase 2
T3011 for bladder cancer not responding to standard treatments
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
Queen Creek, ArizonaAges 18 years+
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscle-invasive bladder carcinoma?
- Yes. Clin2 currently lists 59 recruiting muscle-invasive bladder carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscle-invasive bladder carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscle-invasive bladder carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Muscle Invasive Bladder Cancer
- Muscle Invasive Bladder Cancer (MIBC)
- Non-Muscle Invasive Bladder Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.